高级检索
    曹小龙, 曾康辉. Sotorasib靶向治疗KRAS G12C突变晚期实体肿瘤的疗效及安全性[J]. 循证医学, 2020, 20(5): 261-263. DOI: 10.12019/j.issn.1671-5144.2020.05.002
    引用本文: 曹小龙, 曾康辉. Sotorasib靶向治疗KRAS G12C突变晚期实体肿瘤的疗效及安全性[J]. 循证医学, 2020, 20(5): 261-263. DOI: 10.12019/j.issn.1671-5144.2020.05.002
    shu
    CAO Xiao-long, ZENG Kang-hui. Efficacy and Safety of Sotorasib in Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation[J]. Journal of Evidence-Based Medicine, 2020, 20(5): 261-263. DOI: 10.12019/j.issn.1671-5144.2020.05.002
    Citation: CAO Xiao-long, ZENG Kang-hui. Efficacy and Safety of Sotorasib in Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation[J]. Journal of Evidence-Based Medicine, 2020, 20(5): 261-263. DOI: 10.12019/j.issn.1671-5144.2020.05.002
    shu

    Sotorasib靶向治疗KRAS G12C突变晚期实体肿瘤的疗效及安全性

    Efficacy and Safety of Sotorasib in Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

      摘要
      • HTML全文
      • 参考文献(4)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回